Therapeutic use of anti-CS1 antibodies
View Patent ↗The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
1. A monoclonal antibody or antigen-binding fragment that binds a protein encoded by SEQ ID NO:1, wherein said antibody or antigen binding fragment binds to the same epitope or an overlapping epitope as an antibody obtainable from a hybridoma bearing ATCC designation No. PTA-5950 or an antibody obtainable from a hybridoma hearing ATCC designation No. PTA-5091.
2. The monoclonal antibody or antigen-binding fragment of claim 1 , wherein said monoclonal antibody or antigen-binding fragment is obtainable from a hybridoma bearing ATCC designation No. PTA-5950.
3. The monoclonal antibody or antigen-binding fragment of claim 1 , wherein said monoclonal antibody or antigen-binding fragment is obtainable from a hybridoma bearing ATCC designation No. PTA-5091.
4. The monoclonal antibody or antigen-binding fragment of claim 2 , which is a chimeric, humanized antibody, or a fully human antibody.
5. The monoclonal antibody or antigen-binding fragment of claim 4 , which is a humanized antibody.
6. The monoclonal antibody or antigen-binding fragment of claim 3 , which is a chimeric, humanized antibody, or a fully human antibody.
7. The monoclonal antibody or antigen-binding fragment of claim 6 , which is a humanized antibody.
8. The monoclonal antibody or antigen-binding fragment of claim 2 , wherein said antibody or antigen binding fragment decreases by at least 50% in a competitive binding assay the binding to the protein encoded by SEQ ID NO:1 of a control antibody obtainable from the hybridoma bearing ATCC designation No. PTA-5950.
9. The monoclonal antibody or antigen-binding fragment of claim 3 , wherein said antibody or antigen binding fragment decreases by at least 50% in a competitive binding assay the binding to the protein encoded by SEQ ID NO:1 of a control antibody obtainable from the hybridoma bearing ATCC designation No. PTA-5091.
10. The monoclonal antibody or antigen-binding fragment of claim 5 , wherein said antibody or antigen binding fragment decreases by at least 50% in a competitive binding assay the binding to the protein encoded by SEQ ID NO:1 of a control antibody obtainable from the hybridoma bearing ATCC designation No. PTA-5950.
11. The monoclonal antibody or antigen-binding fragment of claim 7 , wherein said antibody or antigen binding fragment decreases by at least 50% in a competitive binding assay the binding to the protein encoded by SEQ M NO:1 of a control antibody obtainable from the hybridoma bearing ATCC designation No. PTA-5091.
12. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 .